Achieve Life Sciences (ACHV)
(Delayed Data from NSDQ)
$4.58 USD
+0.04 (0.77%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $4.56 -0.02 (-0.33%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.58 USD
+0.04 (0.77%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $4.56 -0.02 (-0.33%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
5 Top Rising P/E Stocks to Enjoy Solid Gains
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Zacks.com highlights: Asbury Automotive, OncoGenex Pharmaceuticals, aTyr Pharma, Avinger and Sunesis Pharmaceuticals
by Zacks Equity Research
Zacks.com highlights: Asbury Automotive, OncoGenex Pharmaceuticals, aTyr Pharma, Avinger and Sunesis Pharmaceuticals
5 Top-Ranked Rising P/E Stocks to Lure Investors
by Sanghamitra Saha
Inside the top-ranked stocks that have been exhibiting rising P/E ratios.
Achieve Life Sciences' Shares Rise on Positive Clinical Data
by Zacks Equity Research
Achieve Life Sciences' (ACHV) pipeline candidate, cytisine, evaluated for smoking cessation, shows no significant interaction with other medication.